PFE

Moderna shares jumped 143% in a month after positive cancer therapy results. The rise raises questions about competition and valuation.

Merck (MRK) has returned about 85% over the past year and at about $150 trades roughly 4% below its 52-week high. A year ago, management spent earnings calls managing fallout from a steep drop in GARDASIL sales. That problem has left the lead. What management opens with instead is a much larger claim, and it settles years from now.

NEW YORK, September 08, 2026--Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the Morgan Stanley 24th Annual Global Healthcare Conference on Monday, September 14, 2026 at 10:45 a.m. EDT.

Medicus Pharma Ltd. (MDCX) has outlined a revised development strategy that makes CD228V, its second-generation antibody-drug conjugate targeting melanotransferrin/CD228, the company’s principal clinical programme.

Lilly is expanding its neuroscience pipeline through growth and acquisitions. The company aims to create a new long‑term driver beyond cardiometabolic therapies.

Four stocks outperformed the S&P 500 and offered yields higher than 30‑year Treasurys. The article suggests investors can pursue both stock gains and high bond yields.

NewAmsterdam Pharma (NAMS) has seen a near 40% stock pullback post-Merck’s Lipfendra approval, but retains multi-blockbuster potential with obicetrapib. Read the latest on the stock here.

Novartis India bought Pfizer brands for $132 million. The acquisition adds a hypertension brand to Novartis’s cardiovascular portfolio.